Key Takeaways
- We score vendors on three factors: price (40%), COA verification (30%), and reputation (30%) — no paid placements
- EZ Peptides ranks first with the broadest verified catalog, competitive pricing, and full COA documentation
- Ascension Peptides offers the best value with 50% off through our link
- Multiple vendors shut down in 2025-2026 — the surviving vendors are stronger for it
- Every vendor listed has a floor score of 8.0 — if they're on this list, they're worth buying from
Most "best peptide vendor" lists are paid placements. A vendor pays for a review, gets ranked first, and the list exists to drive affiliate commissions — not to help you make a good decision.
This list works differently. We score every vendor using a weighted algorithm based on three things that actually matter: price, COA testing, and reputation. No vendor pays for placement. Rankings change when data changes.
Here's how we rank vendors, who makes the cut in 2026, and who to avoid.
How We Score Vendors
Every vendor on this list is evaluated using the same formula:
Score = Price (40%) + COA Verification (30%) + Reputation (30%)
| Factor | Weight | What We Measure |
|---|---|---|
| Price | 40% | Normalized 8-10 against best/worst price per peptide |
| COA | 30% | Third-party Certificate of Analysis availability (has COA = 10, none = 8.0) |
| Reputation | 30% | Track record, community feedback, shipping consistency |
Floor score: 8.0. If a vendor is listed here, they've cleared a quality threshold. We don't list bad vendors and then warn you about them — we just don't list them.
Scores are updated continuously based on real pricing data from our price comparison tool and ongoing quality monitoring.
The Vendor Landscape in 2026
The research peptide market looks fundamentally different than it did 18 months ago.
Multiple major vendors shut down between mid-2025 and early 2026: Peptide Sciences (March 2026), Amino Asylum (FDA raid, June 2025), Paradigm Peptides (criminal guilty plea, December 2025), and Science.bio (January 2026).
The closures were driven by three forces:
- FDA enforcement accelerated — warning letters, warehouse raids, and criminal prosecutions
- Pharmaceutical companies filed lawsuits — Eli Lilly and Novo Nordisk targeted GLP-1 suppliers
- Quality failures were exposed — third-party testing revealed inconsistencies at some major vendors
The silver lining: the vendors that survived are the ones that invested in quality, compliance, and transparency. The bar for operating a peptide vendor has never been higher — and that's good for buyers.
